ClinicalTrials.gov
ClinicalTrials.gov Menu

MEN STUDY (ESTUDIO MEN) Quality of Life in Patients With BPH and Nocturia Before and After Tamsulosin Ocas® Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00885027
Recruitment Status : Completed
First Posted : April 21, 2009
Last Update Posted : November 14, 2013
Sponsor:
Information provided by:
Boehringer Ingelheim

Brief Summary:

This is an exploratory study, to evaluate the improvement in terms of quality of life that can be reached by a group of outpatients with BPH ( Benign Prostatic Hyperplasia ) and nocturia when they are under treatment with Secotex Ocas.

This study will explore, the progress in terms of quality of life that can be reached by a group of outpatients with BPH ( Benign Prostatic Hyperplasia) and nocturia treated with Secotex OCAS®.

This is a not controlled study, " before and after type", which will consist of an assessment, of the quality of life for outpatients with BPH symptoms including nocturia, through the use of the Spanish version of the Nocturia Quality-of-life (NQoL) questionnaire, at three different moments:

  1. Before to start Secotex OCAS® treatment.
  2. Thirty (30) days after first visit and starting Secotex OCAS® treatment
  3. Ninethy (90) days after first visit and starting Secotex Ocas® treatment

Condition or disease
Prostatic Hyperplasia

Detailed Description:
Study Design:

Study Type : Observational
Actual Enrollment : 1342 participants
Time Perspective: Prospective
Official Title: Quality of Life in Patients With BPH and Nocturia Before and After Tamsulosin Ocas® Treatment
Study Start Date : March 2009
Actual Primary Completion Date : April 2009

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Reductions in the intensity of symptoms, evaluated using the IPSS scale. [ Time Frame: up to 90 days ]
  2. Improvement in quality of life, measured using the NQoL questionnaire. [ Time Frame: up to 90 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
men >=40 years old with BPH
Criteria

Inclusion Criteria:

Men 40 years old with benign prostatic hyperplasia (BPH) which, according their doctor, requires medical treatment to improve quality of life. Patients may be new in the treatment or can be treated with other medicines but not having responded adequately to treatment (Not should be taking Tamsulosin OCAS).

PSA < 4.0 ng/ml or 4 ¿ 10ng/ml with prior negative Transrectal biopsy. IPSS > 12 points. Two or more episodes of nocturia per night (score equal or exceed 2 in question 7 of IPSS).

IPSS QoL (Question 8) > 3 points (score equal or superior to 3 in question 8 of Quality of Life (QoL) of IPSS).

Acceptance written of their participation in the study by the informed consent. The decision of treatment should be based on the best clinical practice accepted standard and according to the information for prescription for Secotex OCAS® 0.4 mg.

Exclusion Criteria:

Patients with clear indication to receive surgical treatment Hospitalized patients Patients with physical or mental disabilities that prevent, even with the help of doctor, completing the instruments of assessment of the survey Patients with a history of malignant disease Patients with known hypersensitivity to tamsulosin or to another component of the product Patients with a history of orthostatic hypotension or severe liver failure Positive digital rectal test for possible neoplasia or biochemical evidence of high PSA with figures > 4.0 ng/ml Patients with diastolic blood pressure less than 60 mmHg or tachycardia greater to 120 beats per minute

Other reasons for the exclusion:

  • Acute Urinary Retention (AUR)
  • Urinary tract infection
  • Renal failure

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00885027


Locations
Colombia
Boehringer Ingelheim Investigational Site
Barranquilla, Colombia
Boehringer Ingelheim Investigational Site
Bogotá, Colombia
Boehringer Ingelheim Investigational Site
Boyacá, Colombia
Boehringer Ingelheim Investigational Site
Bucaramanga, Colombia
Boehringer Ingelheim Investigational Site
Cali, Colombia
Boehringer Ingelheim Investigational Site
Cartagena, Colombia
Boehringer Ingelheim Investigational Site
Cúcuta, Colombia
Boehringer Ingelheim Investigational Site
Ibagué, Colombia
Boehringer Ingelheim Investigational Site
Manizales, Colombia
Boehringer Ingelheim Investigational Site
Medellín, Colombia
Boehringer Ingelheim Investigational Site
Palmira, Colombia
Boehringer Ingelheim Investigational Site
Pereira, Colombia
Boehringer Ingelheim Investigational Site
Popayán, Colombia
Boehringer Ingelheim Investigational Site
Santa Marta, Colombia
Boehringer Ingelheim Investigational Site
Sincelejo, Colombia
Boehringer Ingelheim Investigational Site
Tulua, Colombia
Boehringer Ingelheim Investigational Site
Valledupar, Colombia
Boehringer Ingelheim Investigational Site
Villavicencio, Colombia
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim

Responsible Party: Boehringer Ingelheim, Study Chair, Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT00885027     History of Changes
Other Study ID Numbers: 527.80
First Posted: April 21, 2009    Key Record Dates
Last Update Posted: November 14, 2013
Last Verified: November 2013

Additional relevant MeSH terms:
Hyperplasia
Prostatic Hyperplasia
Nocturia
Pathologic Processes
Prostatic Diseases
Genital Diseases, Male
Lower Urinary Tract Symptoms
Urological Manifestations
Signs and Symptoms
Tamsulosin
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Urological Agents